RecruitingPhase 2 / Phase 3NCT05076175
A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis
Sponsor: Bristol-Myers Squibb
Boston, MA · Springfield, MA · Worcester, MA · +33 more sites